189O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle – trial

N. Harbeck; Oleg Gluz; M Christgen; Ulrike Nitz; Manuela Braun; M. Thill; Rachel Würstlein; T. Link; Andreas Hartkopf; Christian Schem; Vesna Bjelic‐Radisic; Mathias Warm; M.K. Graeser-Mayer; Katja Krauss; Oliver Hoffmann; Kerstin Lüedtke-Heckenkamp; Christine zu Eulenburg; P. Schmid; HH Kreipe; Sherko Küemmel

doi:10.1016/j.esmoop.2025.104743

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

WSG ADAPTcycle (NCT 04055493) investigates whether pts with intermediate-risk early breast cancer (EBC) and no endocrine response (ET-resp.) or with intermediate/high-risk EBC and ET-resp. identified by clinical factors, OncotypeDx (RS) and Ki67 ≤10% after preoperative ET, derive survival benefit from ribociclib (Ribo) + ET vs chemotherapy (CT) +ET. (Neo)adjuv. therapy was allowed. We present the first results from ADAPTcycle, addressing optimal treatment in HR+/HER2- EBC with uncertain CT benefit.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Harbeck et al. (2025) studied this question.

synapsesocial.com/papers/69d72916523bf2ea07f50973 https://doi.org/10.1016/j.esmoop.2025.104743

View Full Paper

Ask AI

Bookmark

Share

189O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle – trial

Ask about this paper

Abstract

Discussion

Cite This Study

189O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle – trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading